ID   WIPI1_HUMAN             Reviewed;         446 AA.
AC   Q5MNZ9; Q8IXM5; Q9NWF8;
DT   10-JAN-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2007, sequence version 3.
DT   07-APR-2021, entry version 155.
DE   RecName: Full=WD repeat domain phosphoinositide-interacting protein 1;
DE            Short=WIPI-1;
DE   AltName: Full=Atg18 protein homolog;
DE   AltName: Full=WD40 repeat protein interacting with phosphoinositides of 49 kDa;
DE            Short=WIPI 49 kDa;
GN   Name=WIPI1; Synonyms=WIPI49;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY,
RP   INTERACTION WITH AR; ESR1 AND ESR2, SUBCELLULAR LOCATION, AND VARIANT
RP   ILE-31.
RC   TISSUE=Testis;
RX   PubMed=15602573; DOI=10.1038/sj.onc.1208331;
RA   Proikas-Cezanne T., Waddell S., Gaugel A., Frickey T., Lupas A.,
RA   Nordheim A.;
RT   "WIPI-1alpha (WIPI49), a member of the novel 7-bladed WIPI protein family,
RT   is aberrantly expressed in human cancer and is linked to starvation-induced
RT   autophagy.";
RL   Oncogene 23:9314-9325(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Embryo;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ILE-31.
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   IDENTIFICATION, FUNCTION, SUBCELLULAR LOCATION, BINDING TO
RP   PHOSPHOINOSITIDES, AND MUTAGENESIS OF 226-ARG-ARG-227.
RX   PubMed=15020712; DOI=10.1091/mbc.e03-10-0732;
RA   Jeffries T.R., Dove S.K., Michell R.H., Parker P.J.;
RT   "PtdIns-specific MPR pathway association of a novel WD40 repeat protein,
RT   WIPI49.";
RL   Mol. Biol. Cell 15:2652-2663(2004).
RN   [6]
RP   SUBCELLULAR LOCATION.
RX   PubMed=17618624; DOI=10.1016/j.febslet.2007.06.040;
RA   Proikas-Cezanne T., Ruckerbauer S., Stierhof Y.D., Berg C., Nordheim A.;
RT   "Human WIPI-1 puncta-formation: a novel assay to assess mammalian
RT   autophagy.";
RL   FEBS Lett. 581:3396-3404(2007).
RN   [7]
RP   SUBCELLULAR LOCATION.
RX   PubMed=19590496; DOI=10.1038/emboj.2009.159;
RA   Vergne I., Roberts E., Elmaoued R.A., Tosch V., Delgado M.A.,
RA   Proikas-Cezanne T., Laporte J., Deretic V.;
RT   "Control of autophagy initiation by phosphoinositide 3-phosphatase Jumpy.";
RL   EMBO J. 28:2244-2258(2009).
RN   [8]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=20639694; DOI=10.4161/auto.6.6.12709;
RA   Itakura E., Mizushima N.;
RT   "Characterization of autophagosome formation site by a hierarchical
RT   analysis of mammalian Atg proteins.";
RL   Autophagy 6:764-776(2010).
RN   [9]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=20114074; DOI=10.1016/j.cellsig.2010.01.015;
RA   Grotemeier A., Alers S., Pfisterer S.G., Paasch F., Daubrawa M.,
RA   Dieterle A., Viollet B., Wesselborg S., Proikas-Cezanne T., Stork B.;
RT   "AMPK-independent induction of autophagy by cytosolic Ca2+ increase.";
RL   Cell. Signal. 22:914-925(2010).
RN   [10]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MICROTUBULE-BINDING.
RX   PubMed=20484055; DOI=10.1074/jbc.m109.091553;
RA   Geeraert C., Ratier A., Pfisterer S.G., Perdiz D., Cantaloube I.,
RA   Rouault A., Pattingre S., Proikas-Cezanne T., Codogno P., Pous C.;
RT   "Starvation-induced hyperacetylation of tubulin is required for the
RT   stimulation of autophagy by nutrient deprivation.";
RL   J. Biol. Chem. 285:24184-24194(2010).
RN   [11]
RP   SUBCELLULAR LOCATION.
RX   PubMed=20529838; DOI=10.1074/jbc.m110.118125;
RA   Gao P., Bauvy C., Souquere S., Tonelli G., Liu L., Zhu Y., Qiao Z.,
RA   Bakula D., Proikas-Cezanne T., Pierron G., Codogno P., Chen Q.,
RA   Mehrpour M.;
RT   "The Bcl-2 homology domain 3 mimetic gossypol induces both Beclin 1-
RT   dependent and Beclin 1-independent cytoprotective autophagy in cancer
RT   cells.";
RL   J. Biol. Chem. 285:25570-25581(2010).
RN   [12]
RP   SUBCELLULAR LOCATION.
RX   PubMed=20059746; DOI=10.1111/j.1600-0854.2010.01034.x;
RA   Taguchi-Atarashi N., Hamasaki M., Matsunaga K., Omori H., Ktistakis N.T.,
RA   Yoshimori T., Noda T.;
RT   "Modulation of local PtdIns3P levels by the PI phosphatase MTMR3 regulates
RT   constitutive autophagy.";
RL   Traffic 11:468-478(2010).
RN   [13]
RP   FUNCTION.
RX   PubMed=21317285; DOI=10.1074/jbc.m110.200543;
RA   Ho H., Kapadia R., Al-Tahan S., Ahmad S., Ganesan A.K.;
RT   "WIPI1 coordinates melanogenic gene transcription and melanosome formation
RT   via TORC1 inhibition.";
RL   J. Biol. Chem. 286:12509-12523(2011).
RN   [14]
RP   SUBCELLULAR LOCATION.
RX   PubMed=21564513; DOI=10.1111/j.1582-4934.2011.01339.x;
RA   Proikas-Cezanne T., Robenek H.;
RT   "Freeze-fracture replica immunolabelling reveals human WIPI-1 and WIPI-2 as
RT   membrane proteins of autophagosomes.";
RL   J. Cell. Mol. Med. 15:2007-2010(2011).
RN   [15]
RP   REGULATION BY CALCIUM-SIGNALING, AND SUBCELLULAR LOCATION.
RX   PubMed=21896713; DOI=10.1124/mol.111.071761;
RA   Pfisterer S.G., Mauthe M., Codogno P., Proikas-Cezanne T.;
RT   "Ca2+/calmodulin-dependent kinase (CaMK) signaling via CaMKI and AMP-
RT   activated protein kinase contributes to the regulation of WIPI-1 at the
RT   onset of autophagy.";
RL   Mol. Pharmacol. 80:1066-1075(2011).
RN   [16]
RP   FUNCTION.
RX   PubMed=22829830; DOI=10.1155/2012/179207;
RA   Mauthe M., Yu W., Krut O., Kronke M., Gotz F., Robenek H.,
RA   Proikas-Cezanne T.;
RT   "WIPI-1 positive autophagosome-like vesicles entrap pathogenic
RT   Staphylococcus aureus for lysosomal degradation.";
RL   Int. J. Cell Biol. 2012:179207-179207(2012).
RN   [17]
RP   FUNCTION, DOMAIN, PIP2-BINDING, AND MUTAGENESIS OF SER-203; SER-205;
RP   GLY-208; THR-209; ARG-212; ARG-226; ARG-227; GLY-228; SER-251; THR-255 AND
RP   HIS-257.
RX   PubMed=23088497; DOI=10.1186/1750-2187-7-16;
RA   Gaugel A., Bakula D., Hoffmann A., Proikas-Cezanne T.;
RT   "Defining regulatory and phosphoinositide-binding sites in the human WIPI-1
RT   beta-propeller responsible for autophagosomal membrane localization
RT   downstream of mTORC1 inhibition.";
RL   J. Mol. Signal. 7:16-16(2012).
RN   [18]
RP   FUNCTION, PHOSPHOINOSITIDES-BINDING, INTERACTION WITH ATG16L1; NUDC; WIPI2
RP   AND WDR45, AND SUBCELLULAR LOCATION.
RX   PubMed=28561066; DOI=10.1038/ncomms15637;
RA   Bakula D., Mueller A.J., Zuleger T., Takacs Z., Franz-Wachtel M.,
RA   Thost A.K., Brigger D., Tschan M.P., Frickey T., Robenek H., Macek B.,
RA   Proikas-Cezanne T.;
RT   "WIPI3 and WIPI4 beta-propellers are scaffolds for LKB1-AMPK-TSC signalling
RT   circuits in the control of autophagy.";
RL   Nat. Commun. 8:15637-15637(2017).
CC   -!- FUNCTION: Component of the autophagy machinery that controls the major
CC       intracellular degradation process by which cytoplasmic materials are
CC       packaged into autophagosomes and delivered to lysosomes for degradation
CC       (PubMed:28561066). Plays an important role in starvation- and calcium-
CC       mediated autophagy, as well as in mitophagy (PubMed:28561066).
CC       Functions downstream of the ULK1 and PI3-kinases that produce
CC       phosphatidylinositol 3-phosphate (PtdIns3P) on membranes of the
CC       endoplasmic reticulum once activated (PubMed:28561066). Binds
CC       phosphatidylinositol 3-phosphate (PtdIns3P), and maybe other
CC       phosphoinositides including PtdIns3,5P2 and PtdIns5P, and is recruited
CC       to phagophore assembly sites at the endoplasmic reticulum membranes
CC       (PubMed:28561066). There, it assists WIPI2 in the recruitment of ATG12-
CC       ATG5-ATG16L1, a complex that directly controls the elongation of the
CC       nascent autophagosomal membrane (PubMed:28561066). Involved in
CC       xenophagy of Staphylococcus aureus. Invading S.aureus cells become
CC       entrapped in autophagosome-like WIPI1 positive vesicles targeted for
CC       lysosomal degradation. Plays also a distinct role in controlling the
CC       transcription of melanogenic enzymes and melanosome maturation, a
CC       process that is distinct from starvation-induced autophagy. May also
CC       regulate the trafficking of proteins involved in the mannose-6-
CC       phosphate receptor (MPR) recycling pathway.
CC       {ECO:0000269|PubMed:15020712, ECO:0000269|PubMed:15602573,
CC       ECO:0000269|PubMed:20114074, ECO:0000269|PubMed:20484055,
CC       ECO:0000269|PubMed:20639694, ECO:0000269|PubMed:21317285,
CC       ECO:0000269|PubMed:22829830, ECO:0000269|PubMed:23088497,
CC       ECO:0000269|PubMed:28561066}.
CC   -!- SUBUNIT: Interacts with androgen receptor (AR) and the estrogen
CC       receptors ESR1 and ESR2 (PubMed:15602573). Interacts with WIPI2
CC       (PubMed:28561066). Interacts with WDR45 (PubMed:28561066). Interacts
CC       with ATG16L1 (PubMed:28561066). May interact with NUDC
CC       (PubMed:28561066). {ECO:0000269|PubMed:15602573,
CC       ECO:0000269|PubMed:28561066}.
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus, trans-Golgi network. Endosome.
CC       Cytoplasmic vesicle, clathrin-coated vesicle. Preautophagosomal
CC       structure membrane {ECO:0000269|PubMed:28561066}; Peripheral membrane
CC       protein. Cytoplasm, cytoskeleton. Note=Trans elements of the Golgi and
CC       peripheral endosomes. Dynamically cycles through these compartments and
CC       is susceptible to conditions that modulate membrane flux. Enriched in
CC       clathrin-coated vesicles. Upon starvation-induced autophagy,
CC       accumulates at subcellular structures in the cytoplasm: enlarged
CC       vesicular and lasso-like structures, and large cup-shaped structures
CC       predominantly around the nucleus. Recruitment to autophagic membranes
CC       is controlled by MTMR14. Labile microtubules specifically recruit
CC       markers of autophagosome formation like WIPI1, whereas mature
CC       autophagosomes may bind to stable microtubules.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=WIPI-1 alpha;
CC         IsoId=Q5MNZ9-1; Sequence=Displayed;
CC       Name=2; Synonyms=WIPI-1 beta;
CC         IsoId=Q5MNZ9-2; Sequence=VSP_016966;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed. Highly expressed in
CC       skeletal muscle, heart, testis, pancreas and placenta. Highly expressed
CC       in G361, Sk-mel-28, Sk-mel-13, WM852 and WM451 cells. Up-regulated in a
CC       variety of tumor tissues. {ECO:0000269|PubMed:15602573}.
CC   -!- DOMAIN: The N-terminus might form a beta-propeller domain involved in
CC       specific binding to phosphatidylinositol 3,5-bisphosphate (PIP2),
CC       leading to the association of the protein to the membrane. Association
CC       to the membrane can also occur through binding to phosphatidylinositol
CC       3-monophosphate (PI3P). {ECO:0000269|PubMed:23088497}.
CC   -!- SIMILARITY: Belongs to the WD repeat SVP1 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY691424; AAV80760.1; -; mRNA.
DR   EMBL; AK000917; BAA91423.1; -; mRNA.
DR   EMBL; AC007780; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC039867; AAH39867.1; -; mRNA.
DR   CCDS; CCDS11677.1; -. [Q5MNZ9-1]
DR   RefSeq; NP_001307701.1; NM_001320772.1.
DR   RefSeq; NP_060453.3; NM_017983.6. [Q5MNZ9-1]
DR   SMR; Q5MNZ9; -.
DR   BioGRID; 120380; 16.
DR   IntAct; Q5MNZ9; 11.
DR   STRING; 9606.ENSP00000262139; -.
DR   iPTMnet; Q5MNZ9; -.
DR   PhosphoSitePlus; Q5MNZ9; -.
DR   BioMuta; WIPI1; -.
DR   DMDM; 146291100; -.
DR   jPOST; Q5MNZ9; -.
DR   MassIVE; Q5MNZ9; -.
DR   MaxQB; Q5MNZ9; -.
DR   PaxDb; Q5MNZ9; -.
DR   PeptideAtlas; Q5MNZ9; -.
DR   PRIDE; Q5MNZ9; -.
DR   ProteomicsDB; 63590; -. [Q5MNZ9-1]
DR   ProteomicsDB; 63591; -. [Q5MNZ9-2]
DR   Antibodypedia; 1968; 278 antibodies.
DR   DNASU; 55062; -.
DR   Ensembl; ENST00000262139; ENSP00000262139; ENSG00000070540. [Q5MNZ9-1]
DR   GeneID; 55062; -.
DR   KEGG; hsa:55062; -.
DR   UCSC; uc010dey.4; human. [Q5MNZ9-1]
DR   CTD; 55062; -.
DR   DisGeNET; 55062; -.
DR   GeneCards; WIPI1; -.
DR   HGNC; HGNC:25471; WIPI1.
DR   HPA; ENSG00000070540; Low tissue specificity.
DR   MIM; 609224; gene.
DR   neXtProt; NX_Q5MNZ9; -.
DR   OpenTargets; ENSG00000070540; -.
DR   PharmGKB; PA142670575; -.
DR   VEuPathDB; HostDB:ENSG00000070540.12; -.
DR   eggNOG; KOG2110; Eukaryota.
DR   GeneTree; ENSGT00940000156833; -.
DR   InParanoid; Q5MNZ9; -.
DR   OMA; CIHEGVE; -.
DR   OrthoDB; 1216824at2759; -.
DR   PhylomeDB; Q5MNZ9; -.
DR   TreeFam; TF314879; -.
DR   PathwayCommons; Q5MNZ9; -.
DR   Reactome; R-HSA-1632852; Macroautophagy.
DR   Reactome; R-HSA-381038; XBP1(S) activates chaperone genes.
DR   SignaLink; Q5MNZ9; -.
DR   SIGNOR; Q5MNZ9; -.
DR   BioGRID-ORCS; 55062; 7 hits in 991 CRISPR screens.
DR   ChiTaRS; WIPI1; human.
DR   GeneWiki; WIPI1; -.
DR   GenomeRNAi; 55062; -.
DR   Pharos; Q5MNZ9; Tbio.
DR   PRO; PR:Q5MNZ9; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; Q5MNZ9; protein.
DR   Bgee; ENSG00000070540; Expressed in stromal cell of endometrium and 239 other tissues.
DR   ExpressionAtlas; Q5MNZ9; baseline and differential.
DR   Genevisible; Q5MNZ9; HS.
DR   GO; GO:0000421; C:autophagosome membrane; IDA:UniProtKB.
DR   GO; GO:0030136; C:clathrin-coated vesicle; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0010008; C:endosome membrane; IDA:UniProtKB.
DR   GO; GO:0019898; C:extrinsic component of membrane; IBA:GO_Central.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0000407; C:phagophore assembly site; IDA:UniProtKB.
DR   GO; GO:0034045; C:phagophore assembly site membrane; IDA:UniProtKB.
DR   GO; GO:0005802; C:trans-Golgi network; IDA:UniProtKB.
DR   GO; GO:0050681; F:androgen receptor binding; IDA:UniProtKB.
DR   GO; GO:0030331; F:estrogen receptor binding; IDA:UniProtKB.
DR   GO; GO:0080025; F:phosphatidylinositol-3,5-bisphosphate binding; IDA:UniProtKB.
DR   GO; GO:0032266; F:phosphatidylinositol-3-phosphate binding; IDA:UniProtKB.
DR   GO; GO:0005102; F:signaling receptor binding; IDA:MGI.
DR   GO; GO:0000045; P:autophagosome assembly; IMP:UniProtKB.
DR   GO; GO:0006914; P:autophagy; IEP:UniProtKB.
DR   GO; GO:0000422; P:autophagy of mitochondrion; IBA:GO_Central.
DR   GO; GO:0044804; P:autophagy of nucleus; IBA:GO_Central.
DR   GO; GO:0009267; P:cellular response to starvation; IDA:UniProtKB.
DR   GO; GO:0036498; P:IRE1-mediated unfolded protein response; TAS:Reactome.
DR   GO; GO:0016236; P:macroautophagy; TAS:Reactome.
DR   GO; GO:0006497; P:protein lipidation; IBA:GO_Central.
DR   GO; GO:0034497; P:protein localization to phagophore assembly site; IBA:GO_Central.
DR   GO; GO:0048203; P:vesicle targeting, trans-Golgi to endosome; IDA:UniProtKB.
DR   Gene3D; 2.130.10.10; -; 1.
DR   InterPro; IPR015943; WD40/YVTN_repeat-like_dom_sf.
DR   InterPro; IPR001680; WD40_repeat.
DR   InterPro; IPR036322; WD40_repeat_dom_sf.
DR   InterPro; IPR032909; WIPI1.
DR   PANTHER; PTHR11227:SF23; PTHR11227:SF23; 1.
DR   SMART; SM00320; WD40; 2.
DR   SUPFAM; SSF50978; SSF50978; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Autophagy; Cytoplasm; Cytoplasmic vesicle;
KW   Cytoskeleton; Endosome; Golgi apparatus; Lipid-binding; Membrane;
KW   Reference proteome; Repeat; WD repeat.
FT   CHAIN           1..446
FT                   /note="WD repeat domain phosphoinositide-interacting
FT                   protein 1"
FT                   /id="PRO_0000051437"
FT   REPEAT          3..42
FT                   /note="WD 1"
FT   REPEAT          47..88
FT                   /note="WD 2"
FT   REPEAT          92..126
FT                   /note="WD 3"
FT   REPEAT          131..173
FT                   /note="WD 4"
FT   REPEAT          177..216
FT                   /note="WD 5"
FT   REPEAT          222..261
FT                   /note="WD 6"
FT   REPEAT          304..343
FT                   /note="WD 7"
FT   MOTIF           131..136
FT                   /note="Nuclear receptor interaction"
FT   VAR_SEQ         1..6
FT                   /note="MEAEAA -> M (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_016966"
FT   VARIANT         31
FT                   /note="T -> I (in dbSNP:rs883541)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:15602573"
FT                   /id="VAR_024848"
FT   VARIANT         308
FT                   /note="R -> H (in dbSNP:rs36084378)"
FT                   /id="VAR_053439"
FT   MUTAGEN         203
FT                   /note="S->A: Loss of binding to phosphoinositides and
FT                   abolishes puncta formation."
FT                   /evidence="ECO:0000269|PubMed:23088497"
FT   MUTAGEN         205
FT                   /note="S->A: Loss of binding to phosphoinositides and
FT                   abolishes puncta formation."
FT                   /evidence="ECO:0000269|PubMed:23088497"
FT   MUTAGEN         208
FT                   /note="G->A: Loss of binding to phosphoinositides and
FT                   abolishes puncta formation."
FT                   /evidence="ECO:0000269|PubMed:23088497"
FT   MUTAGEN         209
FT                   /note="T->A: Loss of binding to phosphoinositides and
FT                   abolishes puncta formation."
FT                   /evidence="ECO:0000269|PubMed:23088497"
FT   MUTAGEN         212
FT                   /note="R->A: Loss of binding to phosphoinositides and
FT                   abolishes puncta formation."
FT                   /evidence="ECO:0000269|PubMed:23088497"
FT   MUTAGEN         226..227
FT                   /note="RR->AA: Loss of binding to phosphoinositides, does
FT                   not disrupt the MPR pathway."
FT                   /evidence="ECO:0000269|PubMed:15020712"
FT   MUTAGEN         226
FT                   /note="R->A: Loss of binding to phosphoinositides and
FT                   abolishes puncta formation."
FT                   /evidence="ECO:0000269|PubMed:23088497"
FT   MUTAGEN         227
FT                   /note="R->A: Loss of binding to phosphoinositides and
FT                   abolishes puncta formation."
FT                   /evidence="ECO:0000269|PubMed:23088497"
FT   MUTAGEN         228
FT                   /note="G->A: Loss of binding to phosphoinositides and
FT                   abolishes puncta formation."
FT                   /evidence="ECO:0000269|PubMed:23088497"
FT   MUTAGEN         251
FT                   /note="S->A: Loss of binding to phosphoinositides and
FT                   abolishes puncta formation."
FT                   /evidence="ECO:0000269|PubMed:23088497"
FT   MUTAGEN         255
FT                   /note="T->A: Loss of binding to phosphoinositides and
FT                   abolishes puncta formation."
FT                   /evidence="ECO:0000269|PubMed:23088497"
FT   MUTAGEN         257
FT                   /note="H->A: Loss of binding to phosphoinositides and
FT                   abolishes puncta formation."
FT                   /evidence="ECO:0000269|PubMed:23088497"
FT   CONFLICT        63
FT                   /note="V -> A (in Ref. 1; AAV80760)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        249
FT                   /note="A -> AA (in Ref. 1; AAV80760)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        358
FT                   /note="S -> R (in Ref. 2; BAA91423)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   446 AA;  48673 MW;  35B5650990B62E31 CRC64;
     MEAEAADAPP GGVESALSCF SFNQDCTSLA TGTKAGYKLF SLSSVEQLDQ VHGSNEIPDV
     YIVERLFSSS LVVVVSHTKP RQMNVYHFKK GTEICNYSYS SNILSIRLNR QRLLVCLEES
     IYIHNIKDMK LLKTLLDIPA NPTGLCALSI NHSNSYLAYP GSLTSGEIVL YDGNSLKTVC
     TIAAHEGTLA AITFNASGSK LASASEKGTV IRVFSVPDGQ KLYEFRRGMK RYVTISSLVF
     SMDSQFLCAS SNTETVHIFK LEQVTNSRPE EPSTWSGYMG KMFMAATNYL PTQVSDMMHQ
     DRAFATARLN FSGQRNICTL STIQKLPRLL VASSSGHLYM YNLDPQDGGE CVLIKTHSLL
     GSGTTEENKE NDLRPSLPQS YAATVARPSA SSASTVPGYS EDGGALRGEV IPEHEFATGP
     VCLDDENEFP PIILCRGNQK GKTKQS
//
